SpringWorks Therapeutics Inc - Ordinary Shares
News
TD Asset Management Inc Lowers Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Zolmax TD Asset Management Inc cut its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 31.7% during the second quarter, according to its most recent Form 13F filing with...\n more…
Candriam S.C.A. Has $19.67 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Ticker Report Candriam S.C.A. increased its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 160.2% during the 2nd quarter, HoldingsChannel.com reports. The institutional...\n more…
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
Zacks Investment Research A month has gone by since the last earnings report for SpringWorks Therapeutics (SWTX). Shares have added about 11.7% in that time frame, outperforming the S&P 500.Will the recent positive trend...\n more…
Wall Street Analysts Predict a 61.05% Upside in SpringWorks Therapeutics (SWTX): Here's What You Should Know
Zacks Investment Research SpringWorks Therapeutics (SWTX) closed the last trading session at $40.98, gaining 20.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets...\n more…
SpringWorks Therapeutics (NASDAQ:SWTX) Price Target Increased to $68.00 by Analysts at JPMorgan Chase & Co.
Zolmax SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) had its price target lifted by JPMorgan Chase Co. from $64.00 to $68.00 in a research report sent to investors on Wednesday, Benzinga...\n more…
